Galapagos discovers novel class of antibiotics that kill all MRSA strains

11/27/2012 | Examiner.com

Belgian biotech firm Galapagos said it has identified a new class of antibiotics that demonstrate strong activity against drug-resistant strains of Staphylococcus aureus, including MRSA. The antibiotic acts against an enzyme that is key to the growth of all bacteria, the company said. Galapagos said clinical studies could begin for the antibiotic candidate CAM-1 in early 2014.

View Full Article in:

Examiner.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX